Scarica l'app Stockscreener
298.77
1.20%
-3.635
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$302.41
Aprire:
$302.22
Volume 24 ore:
132.40K
Relative Volume:
0.23
Capitalizzazione di mercato:
$13.47B
Reddito:
$2.99B
Utile/perdita netta:
$1.21B
Rapporto P/E:
11.92
EPS:
25.06
Flusso di cassa netto:
$1.13B
1 W Prestazione:
+8.77%
1M Prestazione:
+2.89%
6M Prestazione:
-14.07%
1 anno Prestazione:
-7.28%
Intervallo 1D:
$298.49
$304.77
Intervallo di 1 settimana:
$283.01
$307.49
Portata 52W:
$266.98
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Confronta UTHR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
298.62 | 13.79B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
148.07 | 65.05B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.32 | 44.85B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.445 | 41.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.08 | 18.02B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
MannKind (MNKD) Q2 Revenue Rises 6% - The Motley Fool
H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating - Insider Monkey
United Therapeutics Announces $1B Accelerated Share Repurchase Program. - AInvest
United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks
United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks
United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey
United Therapeutics stock jumps on $1 billion share repurchase plan - Investing.com
United Therapeutics Launches $1 Bln Stock Buyback - Nasdaq
United Therapeutics Unveils Massive $1B Stock Buyback Plan in Strategic Financial Move - Stock Titan
Pulmonary Arterial Hypertension Drug Market to See Booming - openPR.com
What is the dividend policy of United Therapeutics Corporation stockFree Stock Alerts For Every Investor - Jammu Links News
United Therapeutics Reports Record Q2 2025 Financial Results - The Globe and Mail
BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus - Insider Monkey
United Therapeutics Reports Record Revenue and Growth - TipRanks
H.C. Wainwright lowers United Therapeutics stock price target on Tyvaso competition concerns - Investing.com Nigeria
United Therapeutics Corp (UTHR) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
United Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight - GuruFocus
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment - TipRanks
United Therapeutics Stock Slides On Q2 Earnings: The Details - 富途牛牛
Earnings call transcript: United Therapeutics Q2 2025 misses EPS, stock drops - Investing.com Canada
United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics - Nasdaq
United Therapeutics Q2 2025 slides: Revenue up 12% as Tyvaso drives growth - Investing.com Nigeria
United Therapeutics Logs Growth And Launches Big Buyback - Finimize
United Therapeutics (UTHR) Misses Q2 Earnings Estimates - Yahoo Finance
United Therapeutics misses Q2 earnings expectations By Investing.com - Investing.com South Africa
United Therapeutics misses Q2 earnings expectations - Investing.com
United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates - Yahoo Finance
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
United Therapeutics earnings missed by $0.94, revenue fell short of estimates - Investing.com
United Therapeutics Delivers Triple Win: Record $799M Revenue, $1B Buyback, and Major Pipeline Progress - Stock Titan
United Therapeutics enters $1B accelerated share repurchase program - MSN
United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial - MSN
United Therapeutics’ Promising IPF Treatment Study: A Market Game-Changer? - The Globe and Mail
Preview: United Therapeutics's Earnings - 富途牛牛
Bleecker Street Research short United Therapeutics, long Liquidia - TipRanks
Published on: 2025-07-29 12:41:34 - metal.it
United Therapeutics Earnings Announcement and Market OutlookNews and Statistics - IndexBox
Is There Enough Volume to Lift United Therapeutics CorporationTriple Return Setup With Risk Control Explained - metal.it
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - MSN
Why United Therapeutics Corporation stock attracts strong analyst attentionWeekly Top Gainers Forecast Watchlist Released - metal.it
What institutions are buying United Therapeutics Corporation stock nowEarnings Play Trade Plan With Alerts Shared - metal.it
What To Expect From United Therapeutics’s (UTHR) Q2 Earnings - ca.finance.yahoo.com
ROSEN, A LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Olian Judy D. | Director |
Jul 25 '25 |
Option Exercise |
0.00 |
1,190 |
0 |
6,845 |
| Mesa Nilda | Director |
Jul 25 '25 |
Option Exercise |
0.00 |
590 |
0 |
5,473 |
| KURZWEIL RAY | Director |
Jul 25 '25 |
Option Exercise |
0.00 |
590 |
0 |
12,670 |
| Giltner Richard | Director |
Jul 25 '25 |
Option Exercise |
0.00 |
1,190 |
0 |
20,574 |
| SULLIVAN LOUIS W | Director |
Jul 25 '25 |
Option Exercise |
0.00 |
590 |
0 |
590 |
| CAUSEY CHRISTOPHER | Director |
Jul 25 '25 |
Option Exercise |
0.00 |
1,190 |
0 |
4,865 |
| MALCOLM JAN | Director |
Jun 26 '25 |
Option Exercise |
0.00 |
630 |
0 |
630 |
| MALCOLM JAN | Director |
Jul 25 '25 |
Option Exercise |
0.00 |
590 |
0 |
1,220 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 24 '25 |
Option Exercise |
135.42 |
11,000 |
1,489,620 |
47,781 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 24 '25 |
Sale |
304.11 |
11,000 |
3,345,225 |
36,781 |
1.05%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):